MedTrace Logo

A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro

NCT03733561 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-04-02

No results posted yet for this study

Summary

Phase 1, single center study to assess pharmacokinetic profiles of rotigotine after single dose of LY03003 and daily patch application of Neupro in Healthy Volunteers

Conditions

  • Parkinson Disease

Interventions

DRUG

LY03003

LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)

DRUG

Neupro 4Mg/24Hr Transdermal Patch

neupro patch

Sponsors & Collaborators

  • Luye Pharma Group Ltd.

    lead INDUSTRY

Principal Investigators

  • Paul Rivellese · Sponsor GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-09
Primary Completion
2018-12-23
Completion
2018-12-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03733561 on ClinicalTrials.gov